Search Results - Tim Richardson
- Showing 1 - 6 results of 6
-
1
-
2
-
3
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy by Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy
Published in Journal of Market Access & Health Policy (2018-01-01)Get full text
Article -
4
Early Free Light‐Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA‐Directed CAR‐T Cells by Tim Richardson, Hishan Tharmaseelan, Guido Kobbe, Ben‐Niklas Baermann, Tobias A. W. Holderried, Friederike Schmitz, Martina Crysandt, Philipp Gödel, Nathan Wolfensberger, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick
Published in eJHaem (2025-10-01)Get full text
Article -
5
Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management by Jan‐Michael Werner, Philipp Gödel, Norbert Galldiks, Christopher Krone, Michael Schroeter, Udo Holtick, Ruth Flümann, Gilbert Wunderlich, Michael Hallek, Gereon R. Fink, Christoph Scheid, Oezguer A. Onur, Tim Richardson
Published in HemaSphere (2026-06-01)Get full text
Article -
6
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma by Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, Philipp Gödel
Published in Blood Advances (2025-09-01)Get full text
Article
